Oncotarget

Research Papers:

HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96

Jin Feng _, Junbo Yu, Xiaolin Pan, Zengliang Li, Zheng Chen, Wenjie Zhang, Bin Wang, Li Yang, Hao Xu, Guoxin Zhang and Zekuan Xu

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2014; 5:5832-5844. https://doi.org/10.18632/oncotarget.2200

Metrics: PDF 2421 views  |   HTML 3105 views  |   ?  


Abstract

Jin Feng1*, Junbo Yu1*, Xiaolin Pan3*, Zengliang Li1, Zheng Chen1, Wenjie Zhang1, Bin Wang1, Li Yang1, Hao Xu1, Guoxin Zhang2, Zekuan Xu1

1 Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.

2 Department of Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.

3 Department of Gastroenterology, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China.

* Contributed equally to this paper.

Correspondence to:

Dr. Zekuan Xu, e-mail: [email protected]

Dr. Guoxin Zhang, e-mail: [email protected]

Key words:pancreatic cancer; HERG1; miR-96; anticancer therapy

Received: April 23, 2014     Accepted: July 07, 2014     Published: July 15, 2014

ABSTRACT

Pancreatic cancer is an aggressive malignancy with an extremely poor prognosis. The human ether-a-go-go-related potassium channel (HERG1) is a human rapid delayed rectifier, which is involved in many crucial cellular events. In this article, we find that HERG1 expression is dramatically increased both in pancreatic cancer tissues and cell lines, and that increased HERG1 expression is significantly related to the development of pancreatic cancer. HERG1 silencing in pancreatic cancer-derived cell lines PANC-1 and CFPAC-1 strongly inhibits their malignant capacity in vitro as well as tumorigenicity and metastasis in nude mice. In addition, HERG1 is identified as a direct target of miR-96, which is downregulated in pancreatic cancer tissues and cell lines. Ectopic expression of miR-96 represses the HERG1 expression in pancreatic cancer and significantly inhibits malignant behavior of pancreatic cancer cells in vitro and in vivo.

Collectively, our findings suggest that miR-96 acts as a tumor suppressor in pancreatic cancer and may therefore serve as a useful therapeutic target for the development of new anticancer therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2200